---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-007415"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:55:46.578062+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences prices $8M public offering of common stock and warrants

## Summary
- Gross proceeds ~$8M; offering closed June 5, 2024 with Craig-Hallum as placement agent.
- 61.5M units sold at $0.13 each (or pre-funded at $0.1299), each with Series A and B warrants.
- Series A and B warrants exercisable at $0.22; Series B includes alternate cashless exercise at $0.001 for 3 shares.
- Warrants require stockholder approval and charter amendment; lock-up of 90 days for company/insiders.
- Net proceeds to be used for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001654954-24-007415
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424007415/0001654954-24-007415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424007415/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-007415
- JSON: https://secwatch.observer/filing/0001654954-24-007415.json
- Plain text: https://secwatch.observer/filing/0001654954-24-007415.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.